Repligen (RGEN) Reports In-Line Q4 EPS, provides guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $144.24 +0.21%
Revenue Growth %: +10.7%
Financial Fact:
Net (loss) income: 1.16M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +10.7%
Financial Fact:
Net (loss) income: 1.16M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
(Updated - February 21, 2024 7:40 AM EST)
Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.33, in-line with the analyst estimate of $0.33. Revenue for the quarter came in at $155.7 million versus the consensus estimate of $155.38 million.
GUIDANCE:
Repligen sees 2024 EPS of $1.42-$1.49, versus the consensus of $1.77. Repligen sees 2024 revenue of $620-650 million, versus the consensus of $660.7 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
- FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer
- UBS Reiterates Buy Rating on Dollar Tree (DLTR)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
